Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05317286
Other study ID # CathEF
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2022
Est. completion date February 29, 2024

Study information

Verified date March 2024
Source Montreal Heart Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Left ventricular ejection fraction (LVEF) is one of the strongest predictors of mortality and morbidity in patients with acute coronary syndrome (ACS). Transthoracic echocardiography (TTE) remains the gold standard for LVEF measurement. Currently, LVEF can be estimated at the time of the coronary angiogram but requires a ventriculography. This latter is performed at the price of an increased amount of contrast media injected and puts the patients at risk for mechanical complications, ventricular arrhythmia or atrio-ventricular blocks. Artificial intelligence (AI) has previously been shown to be an accurate method for determining LVEF using different data sources. Fur the purpose of this study, we aim at validating prospectively an AI algorithm, called CathEF, for the prediction of real-time LVEF (AI-LVEF) compared to TTE-LVEF and ventriculography in patients undergoing coronary angiogram for ACS.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date February 29, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informed consent signed by the participant - Acute coronary syndrome - Creatinine clearance =30 ml/min/m2 according to MDRD Exclusion Criteria: - Creatinine clearance <30 ml/min/m2 according to MDRD - No indication to perform TTE in the 7 days following coronary angiogram - Right bundle branch block - Suspected or confirmed left ventricular thrombus - Suspected or confirmed aortic dissection - Ventriculography not feasible - No left coronary system angiogram

Study Design


Locations

Country Name City State
Canada Robert Avram Montreal Quebec

Sponsors (2)

Lead Sponsor Collaborator
Montreal Heart Institute Ottawa Heart Institute Research Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the curve-Receiver Operating Characteristics (AUC-ROC) of the CathEF algorithm for differentiating a LVEF = or >50%, compared to TTE-LVEF Either 7 days before or up to 7 days after the coronary angiogram
Secondary Comparing AUC-ROC of CathEF and ventriculography for differentiating a LVEF = or >50% Either 7 days before or up to 7 days after the coronary angiogram
Secondary Sensitivity of CathEF and ventriculography for differentiating a LVEF = or >50% in comparison to TTE-LVEF. Either 7 days before or up to 7 days after the coronary angiogram
Secondary Specificity of CathEF and ventriculography for differentiating a LVEF = or >50% in comparison to TTE-LVEF. Either 7 days before or up to 7 days after the coronary angiogram
Secondary Number of participants with major adverse cardiovascular events (Combined outcome of combined outcomeof mortality, ventricular arrhythmia requiring an intervention, heart failure, need for inotropic support, renal failure KDIGO=2 and stroke) At 7 days or before discharge, if earlier.
Secondary AUC-ROC of the re-trained CathEF algorthim for differentiating a LEVF = or >50% Either 7 days before or up to 7 days after the coronary angiogram
Secondary Sensitivity of the re-trained CathEF algorthim for differentiating a LEVF = or >50% Either 7 days before or up to 7 days after the coronary angiogram
Secondary Specificity of the re-trained CathEF algorthim for differentiating a LEVF = or >50% Either 7 days before or up to 7 days after the coronary angiogram
Secondary Likert scale on the impact on the procedure, ease of use and utility of the CathEF algorithm in the clinical practice, as assessed by interventional cardiologists Through study completion, an average of 1 year.
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Completed NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study